載入...
3′-Phosphoadenosine 5′-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents
Standard treatment for advanced non-small cell lung cancer (NSCLC) with no known driver mutation is platinum-based chemotherapy, which has a response rate of only 30–33%. Through an siRNA screen, 3′-phosphoadenosine 5′-phosphosulfate (PAPS) synthase 1 (PAPSS1), an enzyme that synthesizes the biologi...
Na minha lista:
發表在: | Oncotarget |
---|---|
Main Authors: | , , , , , , , , , , , |
格式: | Artigo |
語言: | Inglês |
出版: |
Impact Journals LLC
2015
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4627299/ https://ncbi.nlm.nih.gov/pubmed/26220590 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|